Berberine alleviates biofilm-associated immune-inflammatory injury in Staphylococcus aureus-induced osteomyelitis: insights from network pharmacology and experimental validation - Report - MDSpire

Berberine alleviates biofilm-associated immune-inflammatory injury in Staphylococcus aureus-induced osteomyelitis: insights from network pharmacology and experimental validation

  • By

  • Xuan Deng

  • Lin Zhang

  • Jinglin Li

  • Fuyin Yang

  • Chengrui Peng

  • Jiaze Peng

  • Yang Yu

  • Xianpeng Huang

  • Xuxu Yang

  • Lidan Yang

  • July 13, 2026

Share

Berberine Mitigates Immune-Inflammatory Damage in Osteomyelitis

Overview

This study investigates the effects of berberine (BBR) on Staphylococcus aureus-induced osteomyelitis, demonstrating its ability to reduce bacterial viability and inflammatory damage. Its antibacterial efficacy is less than that of clindamycin.

Background

Osteomyelitis is a severe orthopedic infection often caused by Staphylococcus aureus, characterized by biofilm formation and persistent inflammation. The management of this condition is complicated by antibiotic resistance and the need for effective anti-inflammatory strategies. Understanding the role of compounds like berberine could provide new avenues for treatment.

Data Highlights

MeasurementBBR EffectCLD Effect
Bacterial ViabilitySignificantly reducedMore pronounced reduction
Biofilm CoverageDecreasedN/A
Inflammatory MediatorsMarkedly reducedN/A

Key Findings

  • BBR significantly reduced bacterial viability within biofilms.
  • Microscopic observations showed disrupted biofilm architecture after BBR treatment.
  • In vivo, BBR alleviated bone destruction and reduced inflammatory cell infiltration.
  • ELISA results indicated that BBR decreased levels of pro-inflammatory mediators.
  • Network pharmacology identified PTGS2 as a key target of BBR.

Clinical Implications

Berberine should not replace standard antibiotic therapies due to its lower antibacterial efficacy compared to clindamycin.

Conclusion

Berberine demonstrates protective effects against Staphylococcus aureus-induced osteomyelitis.

Related Resources & Content

  1. Frontiers in Medicine, 2026 -- Biogenic Caralluma sinaica-derived silver nanoparticles as a synergistic antibacterial and osteoinductive nanoplatform for osteomyelitis management
  2. the analytical scientist, 2026 -- Gold Nanostars Take SERS Inside the Biofilm
  3. Archives of Orthopaedic and Trauma Surgery, 2026 -- Comparative effectiveness of antimicrobial implant surface coatings in preventing orthopaedic implant-associated infections: a network meta-analysis
  4. 2025 Update to WikiGuidelines for the management of pyogenic osteomyelitis in adults - PubMed
  5. Frontiers in Endocrinology — Adjunctive berberine improves hormonal, metabolic, and inflammatory profiles in women with polycystic ovary syndrome: a retrospective case–control study
  6. 2024 IDSA–ASM laboratory utilization update
  7. Biofilm-active antimicrobial strategies in staphylococcal bone infections
  8. Oral versus Intravenous Antibiotics for Bone and Joint Infection | New England Journal of Medicine

Original Source(s)

Berberine alleviates biofilm-associated immune-inflammatory injury in Staphylococcus aureus-induced osteomyelitis: insights from network pharmacology and experimental validation

  • by Xuan Deng, Lin Zhang, Jinglin Li, Fuyin Yang, Chengrui Peng, Jiaze Peng, Yang Yu, Xianpeng Huang, Xuxu Yang, Lidan Yang

  • July 13, 2026

Related Content

Pharmacokinetic-guided versus weight-guided coagulation factor replacement in hemophilia patients undergoing arthroplasty: a retrospective real-world study on perioperative bleeding risk and economic outcomes

Effect of preoperative tranexamic acid on hidden blood loss and C-reactive protein in patients undergoing Delta-channel endoscopic lumbar discectomy: a retrospective case-control study

A comparative study on percutaneous vertebroplasty for osteoporotic vertebral compression fractures under day surgery and inpatient management models